These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 648565)

  • 1. Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease.
    Tattersall MH; Jarman M; Newlands ES; Holyhead L; Milstead RA; Weinberg A
    Eur J Cancer (1965); 1978 May; 14(5):507-13. PubMed ID: 648565
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral melphalan kinetics.
    Alberts DS; Chang SY; Chen HS; Evans TL; Moon TE
    Clin Pharmacol Ther; 1979 Dec; 26(6):737-45. PubMed ID: 498715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma.
    Bosanquet AG; Gilby ED
    Eur J Cancer Clin Oncol; 1982 Apr; 18(4):355-62. PubMed ID: 6889512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of intravenous melphalan.
    Alberts DS; Chang SY; Chen HS; Moon TE; Evans TL; Furner RL; Himmelstein K; Gross JF
    Clin Pharmacol Ther; 1979 Jul; 26(1):73-80. PubMed ID: 445964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen.
    Woodhouse KW; Hamilton P; Lennard A; Rawlins MD
    Eur J Clin Pharmacol; 1983; 24(2):283-5. PubMed ID: 6840181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases.
    Ardiet C; Tranchand B; Biron P; Rebattu P; Philip T
    Cancer Chemother Pharmacol; 1986; 16(3):300-5. PubMed ID: 3516430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of food on oral melphalan absorption.
    Reece PA; Kotasek D; Morris RG; Dale BM; Sage RE
    Cancer Chemother Pharmacol; 1986; 16(2):194-7. PubMed ID: 3948305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of high dose melphalan.
    Hersh MR; Ludden TM; Kuhn JG; Knight WA
    Invest New Drugs; 1983; 1(4):331-4. PubMed ID: 6678879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of melphalan in children following high-dose intravenous injection.
    Taha IA; Ahmad RA; Rogers DW; Pritchard J; Rogers HJ
    Cancer Chemother Pharmacol; 1983; 10(3):212-6. PubMed ID: 6861266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.
    Loos U; Musch E; Engel M; Hartlapp JH; Hügl E; Dengler HJ
    Eur J Clin Pharmacol; 1988; 35(2):187-93. PubMed ID: 3191937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose melphalan in children with advanced malignant disease. A pharmacokinetic study.
    Ninane J; Baurain R; de Selys A; Trouet A; Cornu G
    Cancer Chemother Pharmacol; 1985; 15(3):263-7. PubMed ID: 4053270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose intravenous melphalan: a review.
    Samuels BL; Bitran JD
    J Clin Oncol; 1995 Jul; 13(7):1786-99. PubMed ID: 7602368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of high-dose melphalan in children and adults.
    Gouyette A; Hartmann O; Pico JL
    Cancer Chemother Pharmacol; 1986; 16(2):184-9. PubMed ID: 3948304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal chemotherapy with melphalan.
    Howell SB; Pfeifle CE; Olshen RA
    Ann Intern Med; 1984 Jul; 101(1):14-8. PubMed ID: 6732077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients.
    Alberts DS; Chen HS; Chang SY; Peng YM
    Recent Results Cancer Res; 1980; 74():293-9. PubMed ID: 6160601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden.
    Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Grimfors G; Gyllenhammar H; Hast R; Johansson B
    Acta Oncol; 1990; 29(6):727-31. PubMed ID: 2223143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
    Smith AC; Liao JT; Page JG; Wientjes MG; Grieshaber CK
    Cancer Res; 1989 Oct; 49(19):5385-91. PubMed ID: 2766304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities.
    Briele HA; Djuric M; Jung DT; Mortell T; Patel MK; Das Gupta TK
    Cancer Res; 1985 Apr; 45(4):1885-9. PubMed ID: 3978649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion.
    Choi KE; Ratain MJ; Williams SF; Golick JA; Beschorner JC; Fullem LJ; Bitran JD
    Cancer Res; 1989 Mar; 49(5):1318-21. PubMed ID: 2645050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.
    McElwain TJ; Hedley DW; Burton G; Clink HM; Gordon MY; Jarman M; Juttner CA; Millar JL; Milsted RA; Prentice G; Smith IE; Spence D; Woods M
    Br J Cancer; 1979 Jul; 40(1):72-80. PubMed ID: 383125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.